TCRvβ8 chimeric antigen receptor natural killer cells exhibit potent preclinical activity against T-cell malignancies

Lianjun He; Yinmei He; Ye He; Xing Bao; Yuqiong Yang; Xueyi Qian; Ziyun Lin; Weijie He; Yao Wu; Huimin Shao; Lingjie Zhou; Lin Wan; Zhenyu Xu

doi:10.1002/ctm2.70004

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (8) : e70004 DOI: 10.1002/ctm2.70004

LETTER TO THE JOURNAL

TCRvβ8 chimeric antigen receptor natural killer cells exhibit potent preclinical activity against T-cell malignancies

Author information +

History +

PDF

Cite this article

Download citation ▾

Lianjun He,Yinmei He,Ye He,Xing Bao,Yuqiong Yang,Xueyi Qian,Ziyun Lin,Weijie He,Yao Wu,Huimin Shao,Lingjie Zhou,Lin Wan,Zhenyu Xu. TCRvβ8 chimeric antigen receptor natural killer cells exhibit potent preclinical activity against T-cell malignancies. Clinical and Translational Medicine, 2024, 14(8): e70004 DOI:10.1002/ctm2.70004

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms published correction appears in leukemia. Leukemia. 2022;36(7):1720-1748.

[2]	Quist-Paulsen P, Toft N, Heyman M, et al. T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia. 2020;34(2):347-357.

[3]	Fleischer LC, Spencer HT, Raikar SS. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J Hematol Oncol. 2019;12(1):141.

[4]	Dai Z, Mu W, Zhao Y. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transduct Target Ther. 2022;7(1):85.

[5]	Rasaiyaah J, Georgiadis C, Preece R, et al. TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight. 2018;3(13):e99442.

[6]	Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature. 1988;334(6181):395-402.

[7]	Paul S, Pearlman AH, Douglass J, et al. TCR β chain-directed bispecific antibodies for the treatment of T cell cancers. Sci Transl Med. 2021;13(584):eabd3595.

[8]	Li F, Zhang H, Wang W, et al. T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies. Nat Commun. 2022;13(1):4334.

[9]	Shaw LC, Poussin M, Rodriguez-Garcia A, et al. TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones. Blood Adv. 2023;7(9):1885-1898.

[10]	Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520-531.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.